Login
$PRPH
$0.36 +$0.00 (0.0%) Close

Company Executives

Officer Age In this role Joined 2024 pay Source
Ted Karkus Also a director
Chairman of the Board and Chief Executive Officer
65 Not stated Not stated $2,123,200
Steven M. Plumb
fractional Chief Financial Officer
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
3
serving now
Independent
2 of 3
stated in the proxy
Average tenure
10.7 years
from year joined
CEO also chairs the board
Yes
Ted Karkus
Director Age On board Independent Committees Other public boards 2024 pay Source
Ted Karkus
65 2009
16 years
Not independent None stated None stated Paid as CEO
Louis Gleckel, MD
69 2009
16 years
Independent
Audit Committee Compensation Committee Nominating and Corporate Governance Committee · Chair
None stated $189,250
Carolina Abenante
55 2025
0 years
Independent
Nominating and Corporate Governance Committee Compensation Committee · Chair
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Jun 23, 2025
Jason Karkus
son of Ted Karkus, our Chairman and Chief Executive Officer
Amount not stated
2024

Compensation paid to Jason Karkus as President of Nebula Genomics, including base salary, bonus, vehicle allowance, 401(k) matching contribution and stock options

With Nebula Genomics, a wholly-owned subsidiary of the Company Open in proxy
Ted Karkus
Chief Executive Officer and Chairman of the Board of Directors
$500,000 cash investment
June 22, 2025

Loan agreement under which Ted Karkus provided a $500,000 cash investment to the Company at a 20% original issue discount, bearing 10% interest, maturing in twelve months, not convertible

With the Company Open in proxy
Amount not stated

500,000 warrants to purchase common stock issued to Ted Karkus as a term of the Loan Agreement, exercise price $0.60, not vested until shareholder approval of an increase in authorized shares

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support